ArticleBMC infectious diseases2022
Streptococcal and Staphylococcus aureus prosthetic joint infections: are they really different?
Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 17 citations in OpenAlex.
- Prevalence and clinical impact of dento-alveolar foci in periprosthetic joint infections: a retrospective cohort study of 213 cases.Infection · 2026Article
- Outcome of guided persistent fistula as a salvage procedure in patients with chronic periprosthetic joint infection.International orthopaedics · 2026Article
- Comparative Analysis of Methicillin-SusceptibleAntibiotics (Basel, Switzerland) · 2026Article
- Efficiency of NSAIDs in preventing prosthetic joint infections (PJIs): inhibition of Staphylococcus aureus biofilms by etoricoxib through down regulation of bacterial adhesion genes.Archives of microbiology · 2026Article
- Periprosthetic joint infection after arthroplasty: advances and future prospects.Journal of orthopaedic surgery and research · 2025Review
- Periprosthetic Joint Infection byLife (Basel, Switzerland) · 2025Article
- Organism profiles and empirical treatments for periprosthetic joint infections.Journal of orthopaedic surgery and research · 2025Article
- Proteomic signatures ofBiofilm · 2025Article
- Outcomes of Staphylococcal Prosthetic Joint Infection After Hip Hemiarthroplasty: Single Center Retrospective Study.Medicina (Kaunas, Lithuania) · 2025Article
- Not All Antiseptic Solutions Are Equivalent in Removing Biofilm: A Comparison Across Different Orthopaedic Surfaces.The Journal of bone and joint surgery. American volume · 2025Article
- Tissue niche influences immune and metabolic profiles to Staphylococcus aureus biofilm infection.Nature communications · 2024Article
- [Arthroplasty and oral health-an overview].Orthopadie (Heidelberg, Germany) · 2024Review
- Never mind the bug: no differences in infection-free survival after periprosthetic joint infections withFrontiers in microbiology · 2024Article
- Global Trends in Orthopedic Biofilm Research: A Bibliometric Analysis of 1994-2022.Journal of multidisciplinary healthcare · 2024Article
- Periprosthetic Joint Infection Diagnosis: A Narrative Review.Antibiotics (Basel, Switzerland) · 2023Review
- Antibiotic Therapy for Prosthetic Joint Infections: An Overview.Antibiotics (Basel, Switzerland) · 2022Review
- Pulsatile Lavage Is Not Enough to Remove Implant Biofilm: An In Vitro Evaluation of Sonication Brushing.JB & JS open accessArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStaphylococci and streptococci are the most frequent pathogens isolated from prosthetic joint infections (PJIs). The aim of this study was to analyze the outcome of streptococcal and methicillin-susceptible Staphylococcus aureus (MSSA) PJIs.
methodsAll monomicrobial streptococcal and MSSA PJIs managed in a French Referral Center (2010-2017) were sampled from the prospective PJIs cohort study. The primary outcome of interest was the cumulative reinfection-free survival at a 2-year follow-up.
resultsTwo hundred and nine patients with 91 streptococcal and 132 staphylococcal infections were analyzed. Patients with streptococcal PJI were older, and infection was more frequently hematogenous. Reinfection-free survival rates at 2-years after all treatment strategies were higher for patients with streptococcal PJI (91% vs 81%; P = .012), but differed according to the strategy. After exchange arthroplasty, no outcome differences were observed (89% vs 93%; P = .878); after debridement, antibiotics and implant retention (DAIR), the reinfection-free survival rate was higher for patients with streptococcal PJI (87% vs 60%; P = .062). For patients managed with prolonged suppressive antibiotic therapy (SAT) alone, those with streptococcal PJIs had a 100% infection-free survival (100% vs 31%; P < .0001).
conclusionsReinfection-free survival after DAIR and SAT was better for patients with streptococcal than those with MSSA PJIs. No difference was observed after prosthesis exchange.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.